[New views on the treatment of chronic myelocytic leukemia. Literature review].
The expansion of knowledge of molecular biology and pathophysiology of chronic myeloid leukaemia (CML) indicate a new therapeutic approaches of the disease. Besides less toxic nonmyeloablative regimes of allogenEic transplantation and the introduction of modified interpherone regimes attracts our interest therapy more specific, aimed to a primary reason of a disease, BCR/ABL gene, and its products, that are responsible for leukaemic transformation. The paper is a summary of experimental, as well as first clinical experiences with application of thyrosinkinase-inhibitors, farnesyl-transferase-inhibitors and vaccination therapy of CML. Even thought is allogeneic transplantation the only curative therapy of CML, first clinical experiences with thyrosinkinase inhibitors show, that these are the medicaments that can become in a near future its important alternative.
Tóthová
E
E
Klinika hematológie LF UPJS a FNsP, Kosice, Slovenská republika.
D006801:Humans; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000628:therapy*